We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

256 hedge funds and large institutions have $4.2B invested in Pacific Biosciences in 2021 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 87 increasing their positions, 79 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 40

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

10% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 79

4% more funds holding

Funds holding: 246 → 256 (+10)

3% more call options, than puts

Call options by funds: $21M | Put options by funds: $20.4M

1.87% less ownership

Funds ownership: 94.96% → 93.09% (-1.9%)

13% less capital invested

Capital invested by funds: $4.83B → $4.2B (-$629M)

Holders
256
Holders Change
+10
Holders Change %
+4.07%
% of All Funds
3.94%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.08%
New
51
Increased
87
Reduced
79
Closed
40
Calls
$21M
Puts
$20.4M
Net Calls
+$570K
Net Calls Change
+$16.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$88.3M
2
Invesco
Invesco
Georgia
+$74.9M
3
NAMA
Nikko Asset Management Americas
New York
+$61.9M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$61.9M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$44.8M

Top Sellers

1
HA
HHLR Advisors
Cayman Islands
-$23.3M
2
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$21.2M
3
EAM
Eagle Asset Management
Florida
-$14.9M
4
SIG
Senator Investment Group
New York
-$14.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$13M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
26
Bellevue Group
Switzerland
$31.8M -$2.18M -90,136 -5%
OIM
27
Oracle Investment Management
Connecticut
$29.1M -$587K -24,307 -2%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$24.2M -$8.69M -360,118 -23%
N
29
Nuveen
North Carolina
$24M -$1.85M -76,841 -6%
Morgan Stanley
30
Morgan Stanley
New York
$22.7M -$10.6M -438,882 -28%
N
31
Natixis
France
$21.7M +$23.7M +980,439 +1,207%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$20.6M +$283K +11,720 +1%
Westfield Capital Management
33
Westfield Capital Management
Massachusetts
$17.6M -$21.2M -878,542 -51%
BLAM
34
Bourne Lent Asset Management
New York
$11.4M +$70K +2,900 +0.5%
GIM
35
Granahan Investment Management
Massachusetts
$10M +$883K +36,593 +8%
Millennium Management
36
Millennium Management
New York
$9.38M +$1.67M +69,124 +18%
Bank of America
37
Bank of America
North Carolina
$9.33M +$4.74M +196,212 +76%
Mirae Asset Global Investments
38
Mirae Asset Global Investments
South Korea
$9.13M +$2.31M +95,609 +27%
GC
39
Guggenheim Capital
Illinois
$8.57M +$1.96M +81,136 +24%
Swiss National Bank
40
Swiss National Bank
Switzerland
$8.5M -$21.7K -900 -0.2%
BPC
41
Banque Pictet & Cie
Switzerland
$8.27M +$8.64M +358,013 +773%
Two Sigma Investments
42
Two Sigma Investments
New York
$7.96M -$12.9M -532,651 -58%
California Public Employees Retirement System
43
California Public Employees Retirement System
California
$7.87M -$1.32M -54,772 -12%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$7.82M -$4.31M -178,400 -32%
Citadel Advisors
45
Citadel Advisors
Florida
$7.25M -$1.22M -50,549 -12%
WCM Investment Management
46
WCM Investment Management
California
$6.92M +$869K +36,012 +12%
PVI
47
Pura Vida Investments
New York
$6.75M -$244K -10,110 -3%
Deutsche Bank
48
Deutsche Bank
Germany
$6.63M -$1.57M -65,213 -17%
Barclays
49
Barclays
United Kingdom
$6.52M +$4.98M +206,485 +184%
JP Morgan Chase
50
JP Morgan Chase
New York
$5.47M +$460K +19,052 +8%
1
2
3 4 5

PACB Hedge Fund Activity: Q4 2021 in Review

256 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2021, worth a combined $4.2B — down 13% from $4.83B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new PACB positions and 40 closed out — a net gain of 11 holders — while 87 added to existing stakes and 79 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $88.3M. The largest seller was HHLR Advisors, exiting entirely with an estimated $23.3M sold.

  • 256 institutional investors held Pacific Biosciences (PACB) as of Q4 2021, up from 246 in Q3 2021.
  • Funds reported $4.2B of Pacific Biosciences stock for Q4 2021, down 13% quarter-over-quarter.
  • 51 funds opened new Pacific Biosciences positions in Q4 2021 and 40 closed out, a net change of +11 holders.
  • The largest Pacific Biosciences buyer in Q4 2021 was ARK Investment Management, an estimated $88.3M added.
  • The largest Pacific Biosciences seller in Q4 2021 was HHLR Advisors, an estimated $23.3M sold.

Based on aggregated 13F filings for Q4 2021.